Table 3.
Univariate and multivariate analyses for overall survival in 98 NSCLC patients treated with neoadjuvant chemotherapy
| Characteristics | No. of patients | HR (95% CI) | P |
|---|---|---|---|
| Univariate analyses | |||
| Age (continuous) | 98 | 1.00 (0.97–1.04) | .830 |
| Gender | |||
| Female (reference) | 44 | 1.00 | .070 |
| Male | 54 | 0.5 (0.23–1.07) | |
| Histology | |||
| Adenocarcinoma (Reference) | 49 | 1.00 | .220 |
| Squamous cell carcinoma | 26 | 0.56 (0.26–1.20) | |
| Other | 23 | 0.62 (0.29–1.31) | |
| Pathological stage | |||
| 0/IA/IB (reference) | 33 | 1.00 | .008 |
| IIA/IIB | 29 | 0.73 (0.31–1.72) | |
| IIA/IIB | 33 | 2.52 (1.27–5.03) | |
| IV | 3 | 2.78 (0.63–12.35) | |
| %Viable tumor cells (continuous) | 98 | 1.02 (1.01–1.03) | .004 |
| EZH2 (continuous) | 98 | 1.00 (0.99–1.01) | .510 |
| VEGFR2 (continuous) | 98 | 1.00 (0.99–1.01) | .680 |
| ERCC1 (continuous) | 98 | 0.99 (0.99–1.00) | .650 |
| RAD51 (continuous) | 98 | 1.01 (1.00–1.01) | .02 |
| PKR (continuous) | 98 | 1.00 (0.99–1.01) | .980 |
| %Viable tumor cells | |||
| ≤10% (or <=10%) (MPR+) (reference) | 8 | 1.00 | .030 |
| >10% (MPR−) | 90 | 3.05 (1.07–8.72) | |
| RAD51 | |||
| Low (reference) | 75 | 1.00 | .005 |
| High | 23 | 2.41 (1.31–4.43) | |
| Multivariate analyses | |||
| Pathological stage | |||
| 0/IA/IB (reference) | 33 | 1.00 | .007 |
| IIA/IIB | 29 | 0.74 (0.31–1.76) | |
| IIA/IIB | 33 | 2.63 (0.32–1.76) | |
| IV | 3 | 2.34 (1.32–5.22) | |
| %Viable tumor cells (continuous) | 98 | 1.01 (1.00–1.03) | .040 |
| RAD51 (continuous) | 98 | 1.01 (1.00–1.01) | .020 |
| %Viable tumor cells | 98 | .040 | |
| ≤10% (or <=10%) (MPR+) (reference) | 8 | 1.00 | |
| >10% (MPR−) | 90 | 2.91 (1.06–7.65) | |
| RAD51 | |||
| Low (reference) | 75 | 1.00 | .004 |
| High | 23 | 2.63 (1.35–5.13) | |
CI, confidence interval; HR, hazard ratio.